|
| |
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
First published online October 21, 2005
Journal of Experimental Biology 208, v-a (2005)
Copyright © 2005 The Company of Biologists Limited
doi: 10.1242/jeb.01890
Outside JEB |
MOVING WITHOUT DOPAMINE
Otto-von-Guericke Universitaet
Magdeburg
susan.sangha{at}medizin.unimagdeburg.de
|
Parkinson's disease (PD), a condition characterized by muscle stiffness and uncontrollable shaking, is caused by the progressive degeneration of midbrain neurons that control motor function. These neurons produce the neurotransmitter dopamine (DA), which has long been associated with motor function. As the neurons deteriorate, dopamine levels plummet, eventually leading to the symptoms of this debilitating disease. To understand the pathological processes leading to PD, researchers have developed rodent models that either recapitulate the loss of DA or recapitulate the neurodegenerative process. But many of these models only achieve incomplete DA depletion, often precluding an accurate recapitulation of the neurological manifestations of PD. Now, Tatyana Sotnikova and colleagues have successfully induced a reliable but transient recapitulation of PD symptoms in mice.
Normally, neurons have a large intracellular storage pool of DA. After its
release, DA is rapidly recycled back into neurons' dopaminergic terminals by
the dopamine transporter (DAT). To create their new PD model, the team knocked
out the dopamine transporter in a group of mice, creating DAT-KO mice that
have virtually no intracellular DA stores. Unlike normal mice, which have
plenty of dopamine in storage, DAT-KO mice depend upon the DA produced by
ongoing synthesis. So, by blocking DA synthesis in these mice, the team could
now eliminate all DA in these animals. When they administered the DA synthesis
inhibitor 
MT to the DAT-KO mice, the animals immediately showed
reliable symptoms of PD; they became immobile and displayed extreme rigidity,
body tremors and droopy eyelids. Now that the team had successfully created a
mouse model of PD, they set out to identify drugs that could relieve the
symptoms of PD. They first tested the effects of administering
L-DOPA, a DA precursor that is commonly given to PD patients, to
DAT-KO mice. They discovered that L-DOPA is just as effective in
mice as it is in humans in the early stages of PD; the drug successfully
restored locomotion in DAT-KO mice. Testing several amphetamine derivatives,
the authors discovered that MDMA (better known as ecstasy) also restored
movement control sufficiently to allow the mice to move forwards. Since
amphetamines are thought to act through the dopamine system to affect
movement, this was a surprising result, because the team was unable to detect
measurable DA levels in the midbrain neurons of these mice. They conclude that
ecstasy must be acting through an unknown DA-independent mechanism. When the
team paired a lower dose of ecstasy with a minimally effective
L-DOPA dose, a synergistic effect occurred: it caused the same
effect as a higher dose of either ecstasy or L-DOPA alone. Thus,
the DA-independent locomotor effect of ecstasy can be markedly enhanced with
additional DA stimulation.
It is currently unclear how this synergistic effect occurs, but amphetamines can clearly affect neuronal systems involved in motor control through mechanisms independent of dopamine. Amphetamines interact with proteins called trace amine receptors, and the authors suggest this interaction as a possible mechanism. Since very little is known about the physiological role of these receptors, more research is needed to delineate the DA-independent mechanism of amphetamines in locomotion. But in the search for new treatments for Parkinson's disease, this study certainly offers a glimmer of hope.
References
Sotnikova, T. D., Beaulieu, J.-M., Barak, L. S., Wetsel, W. C., Caron, M. G. and Gainetdinov, R. R. (2005). Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol. 3, e271.[CrossRef][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
